Advanced Enzyme Technologies Ltd (ADVENZYMES) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Advanced Enzyme Technologies Ltd. (AET) reported steady growth in Q3 FY25, with improved operating performance and financial stability.
- Revenue reached Rs. 1,691 million, a 5% YoY increase and a 16% QoQ rise. However, adjusting for Rs. 80 million in delayed revenue recognition from Q2 FY25, Q3 revenue would be Rs. 1,610 million and Q2 revenue would be Rs. 1,540 million, representing a 5% QoQ growth.
- EBITDA stood at Rs. 553 million, up 3% YoY and 30% QoQ, with a margin of 33%. PAT margin was 23%.
- The company established Starya Labs, an independent laboratory under its U.S. subsidiary, to address customer challenges related to enzyme and probiotic application and testing.
- AET maintains a focus on R&D and product portfolio strategies tailored to specific geographical markets, seeking new opportunities and developing new products and molecules.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.